| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Department of Pediatrics, University of North Carolina, Chapel Hill, North Carolina 27599-7220
Address all correspondence to: Louis E Underwood, M.D., Department of Pediatrics, CB# 7220, University of North Carolina, Chapel Hill, North Carolina 27599-7220.
To investigate whether the anabolic effects of insulin-like growth factor I (IGF-I) and GH are mediated through regulation of the ubiquitin (Ub) pathway, we examined the effect of IGF-I (0.35 µg/100 g) and/or GH (0.3 mg/100 g BW) on the expression of Ub and Ub-conjugating (E2) enzyme messenger RNAs (mRNAs) in skeletal muscle of rats made catabolic by treatment with dexamethasone (Dex; 0.5 mg/100 g BW) for 3 days. Dex caused a significant loss of body and gastrocnemius weight (14% and 25%, respectively) concurrent with an increase in the 2.8- and 1.2-kb transcripts of Ub (14.3- and 12-fold increases, respectively), the 1.8- and 1.2-kb transcripts of 14-kDa Ub-conjugating enzyme (E214 kDa; 5.6- and 7.7-fold increases, respectively), the 4.4- and 2.4-kb transcripts of Ub-E2G (6.5- and 8.2-fold increases, respectively), and the 2E isoform of the 17-kDa E2 mRNA (3.5-fold increase). Injections of IGF-I in Dex-treated animals ameliorated the body weight loss, and the gastrocnemius tended to be heavier. This improvement was also accompanied by a significant suppression of transcripts for Ub (58% and 66% decreases), E214 kDa (58% and 68% decreases), and Ub-E2G (78% decrease), whereas the 2E isoform of the 17-kDa E2 was only modestly affected (20% decrease). GH restored serum IGF-I levels to normal in Dex-treated rats, but had no effect on the body weight loss or on any of the studied components of the Ub pathway. Administration of IGF-I to the Dex/GH-treated animals decreased the activated mRNAs of the Ub pathway in a manner and degree similar to those observed in the Dex/IGF-I group.
In summary, these results provide evidence that IGF-I regulates the expression of mRNAs encoding components of the Ub pathway during catabolism and suggest a possible mechanism for the antiproteolytic actions of IGF-I. On the other hand, GH, which is believed not to affect proteolysis but only protein synthesis, had no effect on any of the mRNAs studied.
This article has been cited by other articles:
![]() |
P. Sundaram, Z. Pang, M. Miao, L. Yu, and S. S. Wing USP19-deubiquitinating enzyme regulates levels of major myofibrillar proteins in L6 muscle cells Am J Physiol Endocrinol Metab, December 1, 2009; 297(6): E1283 - E1290. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Frost, G. J. Nystrom, L. S. Jefferson, and C. H. Lang Hormone, cytokine, and nutritional regulation of sepsis-induced increases in atrogin-1 and MuRF1 in skeletal muscle Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E501 - E512. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. Lang, D. Huber, and R. A. Frost Burn-induced increase in atrogin-1 and MuRF-1 in skeletal muscle is glucocorticoid independent but downregulated by IGF-I Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2007; 292(1): R328 - R336. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Granado, A I Martin, T Priego, A Lopez-Calderon, and M A Villanua Tumour necrosis factor blockade did not prevent the increase of muscular muscle RING finger-1 and muscle atrophy F-box in arthritic rats. J. Endocrinol., October 1, 2006; 191(1): 319 - 326. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Costelli, M. Muscaritoli, M. Bossola, F. Penna, P. Reffo, A. Bonetto, S. Busquets, G. Bonelli, F. J. Lopez-Soriano, G. B. Doglietto, et al. IGF-1 is downregulated in experimental cancer cachexia Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2006; 291(3): R674 - R683. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yimlamai, S. L. Dodd, S. E. Borst, and S. Park Clenbuterol induces muscle-specific attenuation of atrophy through effects on the ubiquitin-proteasome pathway J Appl Physiol, July 1, 2005; 99(1): 71 - 80. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Johnson, S. S. Dritz, K. A. Skjolaas-Wilson, T. E. Burkey, and J. E. Minton Interactive responses in gut immunity, and systemic and local changes in the insulin-like growth factor system in nursery pigs in response to Salmonella enterica serovar Typhimurium J Anim Sci, June 1, 2005; 83(13_suppl): E48 - 56. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Schakman, H. Gilson, V. de Coninck, P. Lause, J. Verniers, X. Havaux, J. M. Ketelslegers, and J. P. Thissen Insulin-Like Growth Factor-I Gene Transfer by Electroporation Prevents Skeletal Muscle Atrophy in Glucocorticoid-Treated Rats Endocrinology, April 1, 2005; 146(4): 1789 - 1797. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. R. Short, J. Nygren, M. L. Bigelow, and K. S. Nair Effect of Short-Term Prednisone Use on Blood Flow, Muscle Protein Metabolism, and Function J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6198 - 6207. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. C. Heszele and S. R. Price Insulin-Like Growth Factor I: The Yin and Yang of Muscle Atrophy Endocrinology, November 1, 2004; 145(11): 4803 - 4805. [Full Text] [PDF] |
||||
![]() |
M. Dehoux, R. Van Beneden, N. Pasko, P. Lause, J. Verniers, L. Underwood, J.-M. Ketelslegers, and J.-P. Thissen Role of the Insulin-Like Growth Factor I Decline in the Induction of Atrogin-1/MAFbx during Fasting and Diabetes Endocrinology, November 1, 2004; 145(11): 4806 - 4812. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. LECKER, R. T. JAGOE, A. GILBERT, M. GOMES, V. BARACOS, J. BAILEY, S. R. PRICE, W. E. MITCH, and A. L. GOLDBERG Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression FASEB J, January 1, 2004; 18(1): 39 - 51. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Fournier, Z.-S. Huang, H. Li, X. Da, B. Cercek, and M. I. Lewis Insulin-like growth factor I prevents corticosteroid-induced diaphragm muscle atrophy in emphysematous hamsters Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2003; 285(1): R34 - R43. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Gregorevic, D. R. Plant, K. S. Leeding, L. A. Bach, and G. S. Lynch Improved Contractile Function of the mdx Dystrophic Mouse Diaphragm Muscle after Insulin-Like Growth Factor-I Administration Am. J. Pathol., December 1, 2002; 161(6): 2263 - 2272. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Fernandez-Celemin, N. Pasko, V. Blomart, and J.-P. Thissen Inhibition of muscle insulin-like growth factor I expression by tumor necrosis factor-alpha Am J Physiol Endocrinol Metab, December 1, 2002; 283(6): E1279 - E1290. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. A. J. Adegoke, N. Bedard, H. P. Roest, and S. S. Wing Ubiquitin-conjugating enzyme E214k/HR6B is dispensable for increased protein catabolism in muscle of fasted mice Am J Physiol Endocrinol Metab, September 1, 2002; 283(3): E482 - E489. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Gomes, S. H. Lecker, R. T. Jagoe, A. Navon, and A. L. Goldberg Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy PNAS, November 15, 2001; (2001) 251541198. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Chrysis, A. S. Calikoglu, P. Ye, and A. J. D'Ercole Insulin-Like Growth Factor-I Overexpression Attenuates Cerebellar Apoptosis by Altering the Expression of Bcl Family Proteins in a Developmentally Specific Manner J. Neurosci., March 1, 2001; 21(5): 1481 - 1489. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Fernandez-Celemin and J.-P. Thissen Interleukin-6 Stimulates Hepatic Insulin-Like Growth Factor Binding Protein-4 Messenger Ribonucleic Acid and Protein Endocrinology, January 1, 2001; 142(1): 241 - 248. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Gomes, S. H. Lecker, R. T. Jagoe, A. Navon, and A. L. Goldberg Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy PNAS, December 4, 2001; 98(25): 14440 - 14445. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Schwartz and R. L. Ruff Changes in contractile properties of skeletal muscle during developmentally programmed atrophy and death Am J Physiol Cell Physiol, June 1, 2002; 282(6): C1270 - C1277. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |